300705 九典制药
已收盘 07-22 15:00:00
资讯
新帖
简况
九典制药:公司股东人数按规定在定期报告中进行披露,请参见公司定期报告
证券之星 · 07-22 18:04
九典制药:公司股东人数按规定在定期报告中进行披露,请参见公司定期报告
九典制药(300705)7月19日主力资金净卖出252.03万元
证券之星 · 07-19
九典制药(300705)7月19日主力资金净卖出252.03万元
九典制药:公司的半自营模式是指由结果导向的粗放式管理逐步过渡为过程管理推进目标达成的精细化管理
证券之星 · 07-17
九典制药:公司的半自营模式是指由结果导向的粗放式管理逐步过渡为过程管理推进目标达成的精细化管理
九典制药(300705)7月2日主力资金净买入447.03万元
证券之星 · 07-02
九典制药(300705)7月2日主力资金净买入447.03万元
九典制药新提交1件商标注册申请
证券之星 · 06-29
九典制药新提交1件商标注册申请
九典制药:平安证券、永赢基金等多家机构于6月27日调研我司
证券之星 · 06-27
九典制药:平安证券、永赢基金等多家机构于6月27日调研我司
6月26日九典制药涨5.73%,安信医药健康股票A基金重仓该股
证券之星 · 06-26
6月26日九典制药涨5.73%,安信医药健康股票A基金重仓该股
九典制药涨5.73%,首创证券一个月前给出“买入”评级
证券之星 · 06-26
九典制药涨5.73%,首创证券一个月前给出“买入”评级
九典制药(300705)6月25日主力资金净买入878.48万元
证券之星 · 06-25
九典制药(300705)6月25日主力资金净买入878.48万元
九典制药:公司股东人数按规定在定期报告中进行披露,请参见公司定期报告
证券之星 · 06-24
九典制药:公司股东人数按规定在定期报告中进行披露,请参见公司定期报告
6月21日九典制药涨5.75%,安信医药健康股票A基金重仓该股
证券之星 · 06-21
6月21日九典制药涨5.75%,安信医药健康股票A基金重仓该股
九典制药涨5.75%,首创证券一个月前给出“买入”评级
证券之星 · 06-21
九典制药涨5.75%,首创证券一个月前给出“买入”评级
九典制药新提交1件商标注册申请
证券之星 · 06-19
九典制药新提交1件商标注册申请
九典制药:公司股东人数按规定在定期报告中进行披露,请参见公司定期报告
证券之星 · 06-11
九典制药:公司股东人数按规定在定期报告中进行披露,请参见公司定期报告
九典制药获得外观设计专利授权:“药品包装礼盒袋(洛索洛芬钠凝胶贴膏)”
证券之星 · 06-05
九典制药获得外观设计专利授权:“药品包装礼盒袋(洛索洛芬钠凝胶贴膏)”
九典制药获东吴证券买入评级,经皮给药新型制剂领先,产品矩阵助力增长
金融界 · 05-23
九典制药获东吴证券买入评级,经皮给药新型制剂领先,产品矩阵助力增长
东吴证券:给予九典制药买入评级
证券之星 · 05-23
东吴证券:给予九典制药买入评级
九典制药(300705.SZ):艾氟洛芬贴剂临床试验申请获批
智通财经 · 05-22
九典制药(300705.SZ):艾氟洛芬贴剂临床试验申请获批
九典制药:招商证券、泰康资产等多家机构于5月20日调研我司
证券之星 · 05-21
九典制药:招商证券、泰康资产等多家机构于5月20日调研我司
九典制药(300705.SZ)2023年度拟每10股派3.21元转增4股 5月24日除权除息
智通财经 · 05-16
九典制药(300705.SZ)2023年度拟每10股派3.21元转增4股 5月24日除权除息
加载更多
公司概况
公司名称:
湖南九典制药股份有限公司
所属行业:
医药制造业
上市日期:
2017-10-10
主营业务:
湖南九典制药股份有限公司主营业务为医药产品的研发、生产和销售,产品主要包括药品制剂、原料药、药用辅料及CXO服务四大类别。公司是国家企业技术中心、国家高技术产业化示范工程企业、国家火炬计划重点高新技术企业、湖南省高新技术企业。公司设有药物研究院,其被认定为湖南省企业技术中心,公司建有博士后科研工作站、新型凝胶膏剂湖南省工程研究中心、湖南省呼吸道药物工程技术研究中心等创新平台。
发行价格:
10.37
{"stockData":{"symbol":"300705","market":"SZ","secType":"STK","nameCN":"九典制药","latestPrice":27.54,"timestamp":1721631834000,"preClose":27.61,"halted":0,"volume":6859705,"delay":0,"floatShares":294000000,"shares":487000000,"eps":0.8572,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.07,"latestTime":"07-22 15:00:00","open":27.59,"high":28.05,"low":27.07,"amount":189000000,"amplitude":0.0355,"askPrice":27.55,"askSize":10,"bidPrice":27.54,"bidSize":18,"shortable":0,"etf":0,"ttmEps":0.8572,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1721698200000},"adr":0,"adjPreClose":27.61,"symbolType":"stock","openAndCloseTimeList":[[1721611800000,1721619000000],[1721624400000,1721631600000]],"highLimit":30.37,"lowLimit":24.85,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":486526829,"pbRate":6.64,"roa":"--","roe":"6.17%","epsLYR":1.07,"committee":-0.079646,"marketValue":13399000000,"floatMarketCap":8102000000,"peRate":32.127857,"changeRate":-0.0025,"turnoverRate":0.0233,"status":1},"requestUrl":"/m/hq/s/300705","defaultTab":"news","newsList":[{"id":"2453757621","title":"九典制药:公司股东人数按规定在定期报告中进行披露,请参见公司定期报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2453757621","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453757621?lang=zh_cn&edition=full","pubTime":"2024-07-22 18:04","pubTimestamp":1721642672,"startTime":"0","endTime":"0","summary":"证券之星消息,九典制药(300705)07月22日在投资者关系平台上答复投资者关心的问题。投资者:您好!请问截至7月20号,公司股东人数是多少?谢谢!九典制药董秘:尊敬的投资者:您好!公司股东人数按规定在定期报告中进行披露,请参见公司定期报告。感谢您对公司的关注!以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024072200024932.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300705","BK0239"],"gpt_icon":0},{"id":"2452541011","title":"九典制药(300705)7月19日主力资金净卖出252.03万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2452541011","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452541011?lang=zh_cn&edition=full","pubTime":"2024-07-19 15:17","pubTimestamp":1721373424,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年7月19日收盘,九典制药报收于27.61元,上涨7.64%,换手率3.83%,成交量11.27万手,成交额3.04亿元。7月19日的资金流向数据方面,主力资金净流出252.03万元,占总成交额0.83%,游资资金净流入1033.96万元,占总成交额3.4%,散户资金净流出781.93万元,占总成交额2.57%。九典制药主营业务:医药产品的研发、生产和销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024071900026523.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300705"],"gpt_icon":0},{"id":"2452399461","title":"九典制药:公司的半自营模式是指由结果导向的粗放式管理逐步过渡为过程管理推进目标达成的精细化管理","url":"https://stock-news.laohu8.com/highlight/detail?id=2452399461","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452399461?lang=zh_cn&edition=full","pubTime":"2024-07-17 18:04","pubTimestamp":1721210651,"startTime":"0","endTime":"0","summary":"证券之星消息,九典制药(300705)07月17日在投资者关系平台上答复投资者关心的问题。投资者:你好,能详细介绍一下公司的半自营模式是怎样一种销售模式吗?九典制药董秘:尊敬的投资者,您好!公司的半自营模式是指由结果导向的粗放式管理逐步过渡为过程管理推进目标达成的精细化管理。感谢您对公司的关注!以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024071700037570.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300705","BK0239"],"gpt_icon":0},{"id":"2448185021","title":"九典制药(300705)7月2日主力资金净买入447.03万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2448185021","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448185021?lang=zh_cn&edition=full","pubTime":"2024-07-02 15:25","pubTimestamp":1719905103,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年7月2日收盘,九典制药报收于26.39元,下跌3.47%,换手率1.18%,成交量3.48万手,成交额9247.2万元。7月2日的资金流向数据方面,主力资金净流入447.03万元,占总成交额4.83%,游资资金净流入423.1万元,占总成交额4.58%,散户资金净流出870.12万元,占总成交额9.41%。九典制药主营业务:医药产品的研发、生产和销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024070200017045.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300705","BK0239"],"gpt_icon":0},{"id":"2447366178","title":"九典制药新提交1件商标注册申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2447366178","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2447366178?lang=zh_cn&edition=full","pubTime":"2024-06-29 12:32","pubTimestamp":1719635572,"startTime":"0","endTime":"0","summary":"证券之星消息,根据企查查数据显示,近日湖南九典制药股份有限公司新提交1件商标注册申请。商标申请详情如下:今年以来湖南九典制药股份有限公司新申请注册商标50件,截止目前公司共持有注册商标578件,另有160件商标尚在注册申请中。数据来源:企查查以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062900013690.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300705"],"gpt_icon":0},{"id":"2446554124","title":"九典制药:平安证券、永赢基金等多家机构于6月27日调研我司","url":"https://stock-news.laohu8.com/highlight/detail?id=2446554124","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446554124?lang=zh_cn&edition=full","pubTime":"2024-06-27 23:14","pubTimestamp":1719501250,"startTime":"0","endTime":"0","summary":"证券之星消息,2024年6月27日九典制药发布公告称平安证券、永赢基金、前海开源、开源证券于2024年6月27日调研我司。答:截至目前,洛索洛芬钠凝胶贴膏已被 27个区域集采,已执行集采的区域有 12 个。九典制药2024年一季报显示,公司主营收入5.91亿元,同比上升17.74%;归母净利润1.26亿元,同比上升63.44%;扣非净利润1.06亿元,同比上升53.9%;负债率28.78%,投资收益58.05万元,财务费用403.25万元,毛利率72.64%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062700041359.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","300705","BK0239"],"gpt_icon":0},{"id":"2446735600","title":"6月26日九典制药涨5.73%,安信医药健康股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2446735600","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446735600?lang=zh_cn&edition=full","pubTime":"2024-06-26 16:28","pubTimestamp":1719390522,"startTime":"0","endTime":"0","summary":"证券之星消息,6月26日九典制药涨5.73%,收盘报27.49元,换手率1.94%,成交量5.74万手,成交额1.54亿元。根据2024基金Q1季报公募基金重仓股数据,重仓该股的公募基金共87家,其中持有数量最多的公募基金为安信医药健康股票A。安信医药健康股票A目前规模为19.52亿元,最新净值0.9416,较上一交易日下跌1.19%,近一年下跌23.07%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062600031830.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300705"],"gpt_icon":0},{"id":"2446356021","title":"九典制药涨5.73%,首创证券一个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2446356021","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446356021?lang=zh_cn&edition=full","pubTime":"2024-06-26 16:28","pubTimestamp":1719390517,"startTime":"0","endTime":"0","summary":"今日九典制药涨5.73%,收盘报27.49元。2024年5月15日,首创证券研究员王斌发布了对九典制药的研报《公司简评报告:外用制剂快速增长,盈利能力稳健提升》,该研报对九典制药给出“买入”评级。此外,中泰证券研究员祝嘉琦,孙宇瑶,财信证券研究员吴号近期也对该股发布了研报,同样给出“买入”评级。证券之星数据中心计算显示,对该股盈利预测较准的分析师团队为开源证券的蔡明子。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062600031827.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601136","300705"],"gpt_icon":0},{"id":"2446000898","title":"九典制药(300705)6月25日主力资金净买入878.48万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2446000898","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446000898?lang=zh_cn&edition=full","pubTime":"2024-06-25 15:30","pubTimestamp":1719300652,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年6月25日收盘,九典制药报收于26.0元,下跌3.17%,换手率1.79%,成交量5.28万手,成交额1.38亿元。6月25日的资金流向数据方面,主力资金净流入878.48万元,占总成交额6.36%,游资资金净流出1037.96万元,占总成交额7.51%,散户资金净流入159.47万元,占总成交额1.15%。九典制药主营业务:医药产品的研发、生产和销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062500024227.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300705","BK0239"],"gpt_icon":0},{"id":"2445028748","title":"九典制药:公司股东人数按规定在定期报告中进行披露,请参见公司定期报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2445028748","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445028748?lang=zh_cn&edition=full","pubTime":"2024-06-24 17:03","pubTimestamp":1719219808,"startTime":"0","endTime":"0","summary":"公司股东人数按规定在定期报告中进行披露,请参见公司定期报告。投资者:请问:2022年以来,贵公司的独家膏药产品在广东浙江等地的集采中标价格确实明显下降,分别降幅25%和28%。这个疑问排除后我会买入贵公司股票,还请务必详细回复,谢谢九典制药董秘:尊敬的投资者,您好!公司产品洛索洛芬钠凝胶贴膏在广东联盟地区集中带量采购最早是2022年12月20日在山西省开始执行,对2022年毛利率影响甚小。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062400023940.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300705","BK0239"],"gpt_icon":0},{"id":"2445738777","title":"6月21日九典制药涨5.75%,安信医药健康股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2445738777","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445738777?lang=zh_cn&edition=full","pubTime":"2024-06-21 16:20","pubTimestamp":1718958051,"startTime":"0","endTime":"0","summary":"证券之星消息,6月21日九典制药涨5.75%,收盘报27.59元,换手率3.78%,成交量11.16万手,成交额3.03亿元。根据2024基金Q1季报公募基金重仓股数据,重仓该股的公募基金共87家,其中持有数量最多的公募基金为安信医药健康股票A。安信医药健康股票A目前规模为19.52亿元,最新净值0.9633,较上一交易日下跌1.45%,近一年下跌22.48%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062100032547.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300705"],"gpt_icon":0},{"id":"2445473870","title":"九典制药涨5.75%,首创证券一个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2445473870","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445473870?lang=zh_cn&edition=full","pubTime":"2024-06-21 16:20","pubTimestamp":1718958045,"startTime":"0","endTime":"0","summary":"今日九典制药涨5.75%,收盘报27.59元。2024年5月15日,首创证券研究员王斌发布了对九典制药的研报《公司简评报告:外用制剂快速增长,盈利能力稳健提升》,该研报对九典制药给出“买入”评级。此外,中泰证券研究员祝嘉琦,孙宇瑶,财信证券研究员吴号近期也对该股发布了研报,同样给出“买入”评级。证券之星数据中心计算显示,对该股盈利预测较准的分析师团队为开源证券的蔡明子。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062100032545.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601136","300705"],"gpt_icon":0},{"id":"2444487684","title":"九典制药新提交1件商标注册申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2444487684","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2444487684?lang=zh_cn&edition=full","pubTime":"2024-06-19 14:04","pubTimestamp":1718777048,"startTime":"0","endTime":"0","summary":"证券之星消息,根据企查查数据显示,近日湖南九典制药股份有限公司新提交1件商标注册申请。商标申请详情如下:今年以来湖南九典制药股份有限公司新申请注册商标46件,截止目前公司共持有注册商标578件,另有156件商标尚在注册申请中。数据来源:企查查以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024061900024857.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300705"],"gpt_icon":0},{"id":"2442873352","title":"九典制药:公司股东人数按规定在定期报告中进行披露,请参见公司定期报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2442873352","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2442873352?lang=zh_cn&edition=full","pubTime":"2024-06-11 17:05","pubTimestamp":1718096738,"startTime":"0","endTime":"0","summary":"证券之星消息,九典制药(300705)06月11日在投资者关系平台上答复投资者关心的问题。投资者:您好!请问截至6月7号,公司股东人数是多少?谢谢!九典制药董秘:尊敬的投资者:您好!公司股东人数按规定在定期报告中进行披露,请参见公司定期报告。感谢您对公司的关注!以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024061100021673.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300705","BK0239"],"gpt_icon":0},{"id":"2441597852","title":"九典制药获得外观设计专利授权:“药品包装礼盒袋(洛索洛芬钠凝胶贴膏)”","url":"https://stock-news.laohu8.com/highlight/detail?id=2441597852","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2441597852?lang=zh_cn&edition=full","pubTime":"2024-06-05 02:28","pubTimestamp":1717525708,"startTime":"0","endTime":"0","summary":"证券之星消息,根据企查查数据显示九典制药新获得一项外观设计专利授权,专利名为“药品包装礼盒袋”,专利申请号为CN202330457029.2,授权日为2024年6月4日。专利摘要:1.本外观设计产品的名称:药品包装礼盒袋。今年以来九典制药新获得专利授权6个,较去年同期增加了20%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024060500003156.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300705","BK0239"],"gpt_icon":0},{"id":"2437270373","title":"九典制药获东吴证券买入评级,经皮给药新型制剂领先,产品矩阵助力增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2437270373","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2437270373?lang=zh_cn&edition=full","pubTime":"2024-05-23 11:32","pubTimestamp":1716435152,"startTime":"0","endTime":"0","summary":"5月23日,九典制药获东吴证券买入评级,近一个月九典制药获得9份研报关注。研报预计2024-2026年公司营业总收入分别为31.04/38.44/45.07亿元,公司归母净利润分别为5.12/6.93/8.65亿元,增速 ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20240523/c658122916.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["601555","300705"],"gpt_icon":0},{"id":"2437627401","title":"东吴证券:给予九典制药买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2437627401","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2437627401?lang=zh_cn&edition=full","pubTime":"2024-05-23 11:17","pubTimestamp":1716434258,"startTime":"0","endTime":"0","summary":"东吴证券股份有限公司朱国广,冉胜男近期对九典制药进行研究并发布了研究报告《经皮给药新型制剂领先,产品矩阵助力增长》,本报告对九典制药给出买入评级,当前股价为35.3元。至2023年报,公司拥有2个凝胶贴膏类药品注册证书,在研外用制剂产品超15个,其中申报生产7个。首次覆盖,给予“买入”评级。最新盈利预测明细如下:该股最近90天内共有8家机构给出评级,买入评级6家,增持评级2家;过去90天内机构目标均价为44.9。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024052300020250.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300705","601555"],"gpt_icon":0},{"id":"2437725491","title":"九典制药(300705.SZ):艾氟洛芬贴剂临床试验申请获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2437725491","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2437725491?lang=zh_cn&edition=full","pubTime":"2024-05-22 17:35","pubTimestamp":1716370509,"startTime":"0","endTime":"0","summary":"智通财经APP讯,九典制药(300705.SZ)发布公告,公司于近日收到国家药品监督管理局签发的《药物临床试验批准通知书》,在完成相关准备工作后将开展临床试验研究。药品名称为艾氟洛芬贴剂,同意其开展用于骨关节炎的镇痛的临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1124545.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","300705","03347","BK1583","BK1141","BK1576"],"gpt_icon":0},{"id":"2437416055","title":"九典制药:招商证券、泰康资产等多家机构于5月20日调研我司","url":"https://stock-news.laohu8.com/highlight/detail?id=2437416055","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2437416055?lang=zh_cn&edition=full","pubTime":"2024-05-21 19:33","pubTimestamp":1716291213,"startTime":"0","endTime":"0","summary":"证券之星消息,2024年5月21日九典制药发布公告称招商证券、泰康资产、国融证券、中华保险、健顺投资、J.P.MORGAN、PUBLIC INVESTMENT FUND于2024年5月20日调研我司。答:椒七麝凝胶贴膏已经在 2023 年 12 月完成了申报生产,预计会在 2025年获批。九典制药主营业务:医药产品的研发、生产和销售。该股最近90天内共有8家机构给出评级,买入评级6家,增持评级2家;过去90天内机构目标均价为44.9。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024052100032770.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK1147","BK0010","300705","BK1564","BK0012","BK0188","BK0276","BK0028","06099","BK0183","600999"],"gpt_icon":0},{"id":"2435675706","title":"九典制药(300705.SZ)2023年度拟每10股派3.21元转增4股 5月24日除权除息","url":"https://stock-news.laohu8.com/highlight/detail?id=2435675706","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2435675706?lang=zh_cn&edition=full","pubTime":"2024-05-16 19:16","pubTimestamp":1715858182,"startTime":"0","endTime":"0","summary":"智通财经APP讯,九典制药(300705.SZ)公告,公司2023年度拟向全体股东每10股派3.21元人民币现金(含税),以资本公积金向全体股东每10股转增4股,本次权益分派股权登记日为2024年5月23日,除权除息日为2024年5月24日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1122171.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","300705"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2017-10-10","address":"湖南省长沙市浏阳市经济技术开发区健康大道1号","stockEarnings":[{"period":"1week","weight":0.0745},{"period":"1month","weight":-0.0018},{"period":"3month","weight":0.1257},{"period":"6month","weight":0.2534},{"period":"1year","weight":0.5606},{"period":"ytd","weight":0.1708}],"companyName":"湖南九典制药股份有限公司","boardCode":"AI0027","perCapita":"41297股","boardName":"医药制造业","registeredCapital":"48652万元","compareEarnings":[{"period":"1week","weight":-0.0033},{"period":"1month","weight":-0.0113},{"period":"3month","weight":-0.0191},{"period":"6month","weight":0.0509},{"period":"1year","weight":-0.0642},{"period":"ytd","weight":-0.0036}],"survey":" 湖南九典制药股份有限公司主营业务为医药产品的研发、生产和销售,产品主要包括药品制剂、原料药、药用辅料及CXO服务四大类别。公司是国家企业技术中心、国家高技术产业化示范工程企业、国家火炬计划重点高新技术企业、湖南省高新技术企业。公司设有药物研究院,其被认定为湖南省企业技术中心,公司建有博士后科研工作站、新型凝胶膏剂湖南省工程研究中心、湖南省呼吸道药物工程技术研究中心等创新平台。","serverTime":1721676684824,"listedPrice":10.37,"stockholders":"7124人(较上一季度减少20.14%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"九典制药(300705)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供九典制药(300705)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"九典制药,300705,九典制药股票,九典制药股票老虎,九典制药股票老虎国际,九典制药行情,九典制药股票行情,九典制药股价,九典制药股市,九典制药股票价格,九典制药股票交易,九典制药股票购买,九典制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"九典制药(300705)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供九典制药(300705)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}